Semin Respir Crit Care Med 2011; 32(3): 274-297
DOI: 10.1055/s-0031-1279825
© Thieme Medical Publishers

Wegener Granulomatosis (Granulomatosis with Polyangiitis): Evolving Concepts in Treatment

Joseph P. Lynch1 , Henry Tazelaar2
  • 1Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, Department of Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, California
  • 2Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona
Further Information

Publication History

Publication Date:
14 June 2011 (online)

ABSTRACT

Wegener granulomatosis (WG), the most common of the pulmonary granulomatous vasculitides, typically involves the upper respiratory tract, lower respiratory tract (bronchi and lung), and kidney, with varying degrees of disseminated vasculitis. The term Granulomatosis with Polyangiitis (Wegener) was recently proposed to replace the older term, WG. The term granulomatosis with polyangiitis can be abbreviated to GPA, with the idea that the eponym Wegener would be omitted over time. Cardinal histologic features include a necrotizing vasculitis involving small vessels, extensive “geographic” necrosis, and granulomatous inflammation. Clinical manifestations of WG are protean; virtually any organ can be involved. The spectrum and severity of the disease are heterogeneous, ranging from indolent disease involving only one site to fulminant, multiorgan vasculitis. The pathogenesis of WG has not been elucidated, but both cellular and humoral components are involved. Circulating antibodies against cytoplasmic components of neutrophils [anti-neutrophil cytoplasmic antibodies (c-ANCAs)] likely play a role in the pathogenesis, and often correlate with activity of the disease. Treatment strategies are evolving. Cyclophosphamide (CYC) plus corticosteroids (CSs) is the mainstay of therapy for generalized, multisystemic WG. Historically, the combination of CYC plus CS was used for a minimum of 12 months, but concern about late toxicities associated with CYC has led to novel treatment approaches. Currently, short-course (3 to 6 months) induction treatment with CYC plus CS, followed by maintenance therapy with less toxic agents (e.g., methotrexate, azathioprine) is recommended. Further, methotrexate combined with CS may be adequate for limited, non-life-threatening WG. Recent studies suggest that rituximab may be useful for induction therapy or CYC-refractory WG. The role of other immunomodulatory agents (including trimethoprim-sulfamethoxazole) is also explored.

REFERENCES

  • 1 Lynch III J P, White E, Tazelaar H, Langford C A. Wegener's granulomatosis: evolving concepts in treatment.  Semin Respir Crit Care Med. 2004;  25 (5) 491-521
  • 2 Hoffman G S, Kerr G S, Leavitt R Y et al.. Wegener granulomatosis: an analysis of 158 patients.  Ann Intern Med. 1992;  116 (6) 488-498
  • 3 Reinhold-Keller E, Beuge N, Latza U et al.. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.  Arthritis Rheum. 2000;  43 (5) 1021-1032
  • 4 Langford C A, Hoffman G S. Rare diseases.3: Wegener's granulomatosis.  Thorax. 1999;  54 (7) 629-637
  • 5 Abdou N I, Kullman G J, Hoffman G S et al.. Wegener's granulomatosis: survey of 701 patients in North America: changes in outcome in the 1990s.  J Rheumatol. 2002;  29 (2) 309-316
  • 6 Falk R J, Gross W L, Guillevin L et al.. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.  Ann Rheum Dis. 2011;  70 (4) 704
  • 7 Falk R J, Jennette J C. ANCA disease: where is this field heading?.  J Am Soc Nephrol. 2010;  21 (5) 745-752
  • 8 Woywodt A, Haubitz M, Haller H, Matteson E L. Wegener's granulomatosis.  Lancet. 2006;  367 (9519) 1362-1366
  • 9 Travis W D. Pathology of pulmonary vasculitis.  Semin Respir Crit Care Med. 2004;  25 (5) 475-482
  • 10 Travis W D, Hoffman G S, Leavitt R Y, Pass H I, Fauci A S. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients.  Am J Surg Pathol. 1991;  15 (4) 315-333
  • 11 Devaney K O, Travis W D, Hoffman G, Leavitt R, Lebovics R, Fauci A S. Interpretation of head and neck biopsies in Wegener's granulomatosis: a pathologic study of 126 biopsies in 70 patients.  Am J Surg Pathol. 1990;  14 (6) 555-564
  • 12 Watts R A, Scott D G. Epidemiology of the vasculitides.  Semin Respir Crit Care Med. 2004;  25 (5) 455-464
  • 13 Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway.  Arthritis Rheum. 2000;  43 (11) 2481-2487
  • 14 Watts R A, Gonzales-Gay M, Garcia-Porrua C, Lane S E, Bentham G, Scott D G. ANCA-associated vasculitis in two European regions.  Clin Exp Immunol. 2000;  120 (suppl 1) 60
  • 15 Watts R A, Al-Taiar A, Scott D G, Macgregor A J. Prevalence and incidence of Wegener's granulomatosis in the UK general practice research database.  Arthritis Rheum. 2009;  61 (10) 1412-1416
  • 16 Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate.  Arthritis Rheum. 2004;  51 (1) 92-99
  • 17 Cotch M F, Hoffman G S, Yerg D E, Kaufman G I, Targonski P, Kaslow R A. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources.  Arthritis Rheum. 1996;  39 (1) 87-92
  • 18 Gibson A, Stamp L K, Chapman P T, O'Donnell J L. The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region.  Rheumatology (Oxford). 2006;  45 (5) 624-628
  • 19 Mohammad A J, Jacobsson L T, Mahr A D, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden.  Rheumatology (Oxford). 2007;  46 (8) 1329-1337
  • 20 Stegmayr B G, Gothefors L, Malmer B, Müller Wiefel D E, Nilsson K, Sundelin B. Wegener granulomatosis in children and young adults: a case study of ten patients.  Pediatr Nephrol. 2000;  14 (3) 208-213
  • 21 Belostotsky V M, Shah V, Dillon M J. Clinical features in 17 paediatric patients with Wegener granulomatosis.  Pediatr Nephrol. 2002;  17 (9) 754-761
  • 22 Rottem M, Fauci A S, Hallahan C W et al.. Wegener granulomatosis in children and adolescents: clinical presentation and outcome.  J Pediatr. 1993;  122 (1) 26-31
  • 23 Grisaru S, Yuen G W, Miettunen P M, Hamiwka L A. Incidence of Wegener's granulomatosis in children.  J Rheumatol. 2010;  37 (2) 440-442
  • 24 Leavitt R Y, Fauci A S, Bloch D A et al.. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.  Arthritis Rheum. 1990;  33 (8) 1101-1107
  • 25 Jennette J C, Falk R J, Andrassy K et al.. Nomenclature of systemic vasculitides. Proposal of an international consensus conference.  Arthritis Rheum. 1994;  37 (2) 187-192
  • 26 Kallenberg C G. Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis.  Curr Opin Rheumatol. 2007;  19 (1) 17-24
  • 27 Kallenberg C G. Pathogenesis of PR3-ANCA associated vasculitis.  J Autoimmun. 2008;  30 (1-2) 29-36
  • 28 Gubbels S P, Barkhuizen A, Hwang P H. Head and neck manifestations of Wegener's granulomatosis.  Otolaryngol Clin North Am. 2003;  36 (4) 685-705
  • 29 Cannady S B, Batra P S, Koening C et al.. Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases.  Laryngoscope. 2009;  119 (4) 757-761
  • 30 Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist's perspective.  Curr Opin Rheumatol. 2001;  13 (1) 3-11
  • 31 Ah-See K W, McLaren K, Maran A G. Wegener's granulomatosis presenting as major salivary gland enlargement.  J Laryngol Otol. 1996;  110 (7) 691-693
  • 32 Gassling V, Wiltfang J, Hampe J, Bräsen J H, Both M, Moosig F. Salivary gland swelling in Wegener's granulomatosis: a rare cause of a frequent symptom.  J Rheumatol. 2010;  37 (12) 2633-2635
  • 33 Bucolo S, Torre V, Montemagno A, Beatrice F. Wegener's granulomatosis presenting with otologic and neurologic symptoms: clinical and pathological correlations.  J Oral Pathol Med. 2003;  32 (7) 438-440
  • 34 Liu S Y, Vlantis A C, Lee W C. Bilateral parotid and submandibular gland enlargement: rare features of Wegener's granulomatosis.  J Laryngol Otol. 2003;  117 (2) 148-150
  • 35 Lloyd G, Lund V J, Beale T, Howard D. Rhinologic changes in Wegener's granulomatosis.  J Laryngol Otol. 2002;  116 (7) 565-569
  • 36 Takwoingi Y M, Dempster J H. Wegener's granulomatosis: an analysis of 33 patients seen over a 10-year period.  Clin Otolaryngol Allied Sci. 2003;  28 (3) 187-194
  • 37 Newman N J, Slamovits T L, Friedland S, Wilson W B. Neuro-ophthalmic manifestations of meningocerebral inflammation from the limited form of Wegener's granulomatosis.  Am J Ophthalmol. 1995;  120 (5) 613-621
  • 38 Haynes B F, Fishman M L, Fauci A S, Wolff S M. The ocular manifestations of Wegener's granulomatosis: fifteen years experience and review of the literature.  Am J Med. 1977;  63 (1) 131-141
  • 39 Fauci A S, Haynes B F, Katz P, Wolff S M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.  Ann Intern Med. 1983;  98 (1) 76-85
  • 40 Woo T L, Francis I C, Wilcsek G A, Coroneo M T, McNab A A, Sullivan T J. Australasian Orbital and Adnexal Wagener's Study Group . Australasian orbital and adnexal Wegener's granulomatosis.  Ophthalmology. 2001;  108 (9) 1535-1543
  • 41 Harper S L, Letko E, Samson C M et al.. Wegener's granulomatosis: the relationship between ocular and systemic disease.  J Rheumatol. 2001;  28 (5) 1025-1032
  • 42 Tarabishy A, Schulte M, Papaliodis G N, Hoffman G S. Wegener's granulomatosis: clinical manifestations, differential diagnosis, and management of ocular and systemic disease.  Surv Ophthalmol. 2010;  55 193-214
  • 43 Valmaggia C, Neuweiler J. Orbital involvement as the first manifestation in classic Wegener's granulomatosis.  Orbit. 2001;  20 (3) 231-237
  • 44 Lamprecht P, Reinhold-Keller E, Gross W L, Reuter M. Clinical images: orbital granuloma and subglottic tracheal stenosis in Wegener's granulomatosis.  Arthritis Rheum. 2000;  43 (7) 1654
  • 45 Niskopoulou M, Du Toit N. Optic neuritis as a feature of Wegener's granulomatosis.  Eye (Lond). 2002;  16 (3) 320-321
  • 46 Blum M, Andrassy K, Adler D, Hartmann M, Völcker H E. Early experience with intravenous immunoglobulin treatment in Wegener's granulomatosis with ocular involvement.  Graefes Arch Clin Exp Ophthalmol. 1997;  235 (9) 599-602
  • 47 Wardyn K A, Ycińska K, Matuszkiewicz-Rowińska J, Chipczyńska M. Pseudotumour orbitae as the initial manifestation in Wegener's granulomatosis in a 7-year-old girl.  Clin Rheumatol. 2003;  22 (6) 472-474
  • 48 Hardwig P W, Bartley G B, Garrity J A. Surgical management of nasolacrimal duct obstruction in patients with Wegener's granulomatosis.  Ophthalmology. 1992;  99 (1) 133-139
  • 49 Pakrou N, Selva D, Leibovitch I. Wegener's granulomatosis: ophthalmic manifestations and management.  Semin Arthritis Rheum. 2006;  35 (5) 284-292
  • 50 Langford C A, Sneller M C, Hallahan C W et al.. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis.  Arthritis Rheum. 1996;  39 (10) 1754-1760
  • 51 Daum T E, Specks U, Colby T V et al.. Tracheobronchial involvement in Wegener's granulomatosis.  Am J Respir Crit Care Med. 1995;  151 (2 Pt 1) 522-526
  • 52 Gluth M B, Shinners P A, Kasperbauer J L. Subglottic stenosis associated with Wegener's granulomatosis.  Laryngoscope. 2003;  113 (8) 1304-1307
  • 53 Screaton N J, Sivasothy P, Flower C D, Lockwood C M. Tracheal involvement in Wegener's granulomatosis: evaluation using spiral CT.  Clin Radiol. 1998;  53 (11) 809-815
  • 54 Lynch III J P, Quint L E. Tracheobronchial and esophageal manifestations of systemic diseases. In: Cummings C E, ed. Otolaryngology Head and Neck Surgery. 3rd ed. St. Louis: Mosby-Year Book; 1998: 2343-2367
  • 55 Quint L E, Whyte R I, Kazerooni E A et al.. Stenosis of the central airways: evaluation by using helical CT with multiplanar reconstructions.  Radiology. 1995;  194 (3) 871-877
  • 56 Nouraei S A, Obholzer R, Ind P W et al.. Results of endoscopic surgery and intralesional steroid therapy for airway compromise due to tracheobronchial Wegener's granulomatosis.  Thorax. 2008;  63 (1) 49-52
  • 57 Gotway M B, Golden J A, LaBerge J M et al.. Benign tracheobronchial stenoses: changes in short-term and long-term pulmonary function testing after expandable metallic stent placement.  J Comput Assist Tomogr. 2002;  26 (4) 564-572
  • 58 Schokkenbroek A A, Franssen C F, Dikkers F G. Dilatation tracheoscopy for laryngeal and tracheal stenosis in patients with Wegener's granulomatosis.  Eur Arch Otorhinolaryngol. 2008;  265 (5) 549-555
  • 59 Hoffman G S, Thomas-Golbanov C K, Chan J, Akst L M, Eliachar I. Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation.  J Rheumatol. 2003;  30 (5) 1017-1021
  • 60 Cordier J F, Valeyre D, Guillevin L, Loire R, Brechot J M. Pulmonary Wegener's granulomatosis: a clinical and imaging study of 77 cases.  Chest. 1990;  97 (4) 906-912
  • 61 Gómez-Puerta J A, Hernández-Rodríguez J, López-Soto A, Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease.  Chest. 2009;  136 (4) 1101-1111
  • 62 Shin M S, Young K R, Ho K J. Wegener's granulomatosis upper respiratory tract and pulmonary radiographic manifestations in 30 cases with pathogenetic consideration.  Clin Imaging. 1998;  22 (2) 99-104
  • 63 Komócsi A, Reuter M, Heller M, Muraközi H, Gross W L, Schnabel A. Active disease and residual damage in treated Wegener's granulomatosis: an observational study using pulmonary high-resolution computed tomography.  Eur Radiol. 2003;  13 (1) 36-42
  • 64 Lynch III J P, Leatherman J W. Alveolar hemorrhage syndromes. In: Fishman A E, ed. Pulmonary Diseases and Disorders. 3rd ed. New York, NY: McGraw-Hill; 1997: 1193-1210
  • 65 Travis W D, Colby T V, Lombard C, Carpenter H A. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation.  Am J Surg Pathol. 1990;  14 (12) 1112-1125
  • 66 Lee K S, Kim T S, Fujimoto K et al.. Thoracic manifestation of Wegener's granulomatosis: CT findings in 30 patients.  Eur Radiol. 2003;  13 (1) 43-51
  • 67 Reuter M, Schnabel A, Wesner F et al.. Pulmonary Wegener's granulomatosis: correlation between high-resolution CT findings and clinical scoring of disease activity.  Chest. 1998;  114 (2) 500-506
  • 68 Sheehan R E, Flint J D, Müller N L. Computed tomography features of the thoracic manifestations of Wegener granulomatosis.  J Thorac Imaging. 2003;  18 (1) 34-41
  • 69 Michael C W, Flint A. The cytologic features of Wegener's granulomatosis.  Am J Clin Pathol. 1998;  110 (1) 10-15
  • 70 Carruthers D M, Connor S, Howie A J et al.. Percutaneous image-guided biopsy of lung nodules in the assessment of disease activity in Wegener's granulomatosis.  Rheumatology (Oxford). 2000;  39 (7) 776-782
  • 71 Uner A H, Rozum-Slota B, Katzenstein A L. Bronchiolitis obliterans-organizing pneumonia (BOOP)-like variant of Wegener's granulomatosis: a clinicopathologic study of 16 cases.  Am J Surg Pathol. 1996;  20 (7) 794-801
  • 72 Katzenstein A L, Locke W K. Solitary lung lesions in Wegener's granulomatosis: pathologic findings and clinical significance in 25 cases.  Am J Surg Pathol. 1995;  19 (5) 545-552
  • 73 Yousem S. Bronchocentric injury in Wegener's granulomatosis: a report of five cases.  Hum Pathol. 1991;  22 534-540
  • 74 Casian A, Jayne D. Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis.  Curr Opin Rheumatol. 2011;  23 (1) 12-17
  • 75 Aasarød K, Bostad L, Hammerstrøm J, Jørstad S, Iversen B M. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis.  Nephrol Dial Transplant. 2001;  16 (5) 953-960
  • 76 Bajema I M, Hagen E C, Hermans J et al.. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis.  Kidney Int. 1999;  56 (5) 1751-1758
  • 77 Mekhail T M, Hoffman G S. Long-term outcome of Wegener's granulomatosis in patients with renal disease requiring dialysis.  J Rheumatol. 2000;  27 (5) 1237-1240
  • 78 Jayne D R, Gaskin G, Rasmussen N European Vasculitis Study Group et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.  J Am Soc Nephrol. 2007;  18 (7) 2180-2188
  • 79 Lionaki S, Falk R J. Removing antibody and preserving glomeruli in ANCA small-vessel vasculitis.  J Am Soc Nephrol. 2007;  18 (7) 1987-1989
  • 80 Szpirt W M, Heaf J G, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis—a clinical randomized controlled trial.  Nephrol Dial Transplant. 2011;  26 206-213
  • 81 Aasarød K, Iversen B M, Hammerstrøm J, Bostad L, Vatten L, Jørstad S. Wegener's granulomatosis: clinical course in 108 patients with renal involvement.  Nephrol Dial Transplant. 2000;  15 (5) 611-618
  • 82 Hensle T W, Mitchell M E, Crooks K K, Robinson D. Urologic manifestations of Wegener granulomatosis.  Urology. 1978;  12 (5) 553-556
  • 83 Huong D L, Papo T, Piette J C et al.. Urogenital manifestations of Wegener's granulomatosis.  Medicine (Baltimore). 1995;  74 (3) 152-161
  • 84 Baker S B, Robinson D R. Unusual renal manifestations of Wegener's granulomatosis: report of two cases.  Am J Med. 1978;  64 (5) 883-889
  • 85 Frigui M, Ben Hmida M, Kechaou M, Jlidi R, Bahloul Z. Wegener's granulomatosis presenting as multiple bilateral renal masses: case report and literature review.  Rheumatol Int. 2009;  29 (6) 679-683
  • 86 Gunnarsson R, Omdal R, Kjellevold K H, Ellingsen C L. Wegener's granulomatosis of the prostate gland.  Rheumatol Int. 2004;  24 120-122
  • 87 Nishino H, Rubino F A, DeRemee R A, Swanson J W, Parisi J E. Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic.  Ann Neurol. 1993;  33 (1) 4-9
  • 88 de Groot K, Schmidt D K, Arlt A C, Gross W L, Reinhold-Keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis.  Arch Neurol. 2001;  58 (8) 1215-1221
  • 89 Holle J U, Gross W L. Neurological involvement in Wegener's granulomatosis.  Curr Opin Rheumatol. 2011;  23 (1) 7-11
  • 90 Weinberger L M, Cohen M L, Remler B F, Naheedy M H, Leigh R J. Intracranial Wegener's granulomatosis.  Neurology. 1993;  43 (9) 1831-1834
  • 91 Garovic V D, Clarke B L, Chilson T S, Specks U. Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis.  Am J Kidney Dis. 2001;  37 (1) E5
  • 92 Woywodt A, Knoblauch H, Kettritz R, Schneider W, Göbel U. Sudden death and Wegener's granulomatosis of the pituitary.  Scand J Rheumatol. 2000;  29 (4) 264-266
  • 93 Mattioli F, Capra R, Rovaris M et al.. Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitides.  J Neurol Sci. 2002;  195 (2) 161-166
  • 94 Murphy J M, Gomez-Anson B, Gillard J H et al.. Wegener granulomatosis: MR imaging findings in brain and meninges.  Radiology. 1999;  213 (3) 794-799
  • 95 Mentzel H J, Neumann T, Fitzek C, Sauner D, Reichenbach J R, Kaiser W A. MR imaging in Wegener granulomatosis of the spinal cord.  AJNR Am J Neuroradiol. 2003;  24 (1) 18-21
  • 96 Comfere N I, Macaron N C, Gibson L E. Cutaneous manifestations of Wegener's granulomatosis: a clinicopathologic study of 17 patients and correlation to antineutrophil cytoplasmic antibody status.  J Cutan Pathol. 2007;  34 (10) 739-747
  • 97 Barksdale S K, Hallahan C W, Kerr G S, Fauci A S, Stern J B, Travis W D. Cutaneous pathology in Wegener's granulomatosis: a clinicopathologic study of 75 biopsies in 46 patients.  Am J Surg Pathol. 1995;  19 (2) 161-172
  • 98 Morelli S, Gurgo Di Castelmenardo A M, Conti F et al.. Cardiac involvement in patients with Wegener's granulomatosis.  Rheumatol Int. 2000;  19 (6) 209-212
  • 99 Kouba D J, Kirsch D G, Mimouni D, Nousari C H. Wegener's granulomatosis with cardiac involvement masquerading as Lyme disease.  Clin Exp Rheumatol. 2003;  21 (5) 647-649
  • 100 Parry S D, Clark D M, Campbell J. Coronary arteritis in Wegener's granulomatosis causing fatal myocardial infarction.  Hosp Med. 2000;  61 (4) 284-285
  • 101 Musuruana J L, Cavallasca J A, Berduc J, Vicario J. Coronary artery aneurysms in Wegener's granulomatosis.  Joint Bone Spine. 2010;  Dec 29. [Epub ahead of print]
  • 102 Schmidt W A, Seipelt E, Molsen H P, Poehls C, Gromnica-ihle E J. Vasculitis of the internal carotid artery in Wegener's granulomatosis: comparison of ultrasonography, angiography, and MRI.  Scand J Rheumatol. 2001;  30 (1) 48-50
  • 103 Blockmans D, Baeyens H, Van Loon R, Lauwers G, Bobbaers H. Periaortitis and aortic dissection due to Wegener's granulomatosis.  Clin Rheumatol. 2000;  19 (2) 161-164
  • 104 Chang Y J, Kerr L D. Isolated abdominal vasculitis as an atypical presentation of Wegener's granulomatosis.  Am J Gastroenterol. 2000;  95 (1) 297-298
  • 105 Haworth S J, Pusey C D. Severe intestinal involvement in Wegener's granulomatosis.  Gut. 1984;  25 (11) 1296-1300
  • 106 Camilleri M, Pusey C D, Chadwick V S, Rees A J. Gastrointestinal manifestations of systemic vasculitis.  Q J Med. 1983;  52 (206) 141-149
  • 107 Steele C, Bohra S, Broe P, Murray F E. Acute upper gastrointestinal haemorrhage and colitis: an unusual presentation of Wegener's granulomatosis.  Eur J Gastroenterol Hepatol. 2001;  13 (8) 993-995
  • 108 Qian Q, Cornell L, Chandan V, Hartman R, Caples S. Hemorrhagic colitis as a presenting feature of Wegener granulomatosis.  J Gastrointestin Liver Dis. 2010;  19 (4) 445-447
  • 109 Sokol R J, Farrell M K, McAdams A J. An unusual presentation of Wegener's granulomatosis mimicking inflammatory bowel disease.  Gastroenterology. 1984;  87 (2) 426-432
  • 110 Zen Y, Sunagozaka H, Tsuneyama K et al.. Incomplete septal cirrhosis associated with Wegener's granulomatosis.  Liver. 2002;  22 (5) 388-393
  • 111 Holl-Ulrich K, Klass M. Wegener s granulomatosis with granulomatous liver involvement.  Clin Exp Rheumatol. 2010;  28 (1, suppl 57) 88-89
  • 112 Rentsch J, McColl G. Splenic infarction in Wegener's granulomatosis.  J Rheumatol. 2000;  27 (6) 1554-1555
  • 113 Kalaitzoglou I, Drevelengas A, Palladas P, Asimaki A. MRI appearance of pulmonary Wegener's granulomatosis with concomitant splenic infarction.  Eur Radiol. 1998;  8 (3) 367-370
  • 114 Boomsma M M, Stegeman C A, van der Leij M J et al.. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study.  Arthritis Rheum. 2000;  43 (9) 2025-2033
  • 115 Gómez-Puerta J A, Bosch X. Anti-neutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update.  Am J Pathol. 2009;  175 (5) 1790-1798
  • 116 Dijstelbloem H M, Scheepers R H, Oost W W et al.. Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse.  Arthritis Rheum. 1999;  42 (9) 1823-1827
  • 117 Savige J A, Chang L, Cook L, Burdon J, Daskalakis M, Doery J. Alpha 1-antitrypsin deficiency and anti-proteinase 3 antibodies in anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis.  Clin Exp Immunol. 1995;  100 (2) 194-197
  • 118 Borgmann S, Endisch G, Urban S, Sitter T, Fricke H. A linkage disequilibrium between genes at the serine protease inhibitor gene cluster on chromosome 14q32.1 is associated with Wegener's granulomatosis.  Clin Immunol. 2001;  98 (2) 244-248
  • 119 Walton E W. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis).  BMJ. 1958;  2 (5091) 265-270
  • 120 Hoffman G S. “Wegener's granulomatosis”: the path traveled since 1931.  Medicine (Baltimore). 1994;  73 (6) 325-329
  • 121 Hollander D, Manning R T. The use of alkylating agents in the treatment of Wegener's granulomatosis.  Ann Intern Med. 1967;  67 (2) 393-398
  • 122 Fauci A S, Wolff S M. Wegener's granulomatosis: studies in eighteen patients and a review of the literature.  Medicine (Baltimore). 1973;  52 (6) 535-561
  • 123 Reinhold-Keller E, Kekow J, Schnabel A et al.. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis.  Arthritis Rheum. 1994;  37 (6) 919-924
  • 124 Guillevin L, Cordier J F, Lhote F et al.. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.  Arthritis Rheum. 1997;  40 (12) 2187-2198
  • 125 Pagnoux C, Hogan S L, Chin H et al.. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.  Arthritis Rheum. 2008;  58 (9) 2908-2918
  • 126 Talar-Williams C, Hijazi Y M, Walther M M et al.. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.  Ann Intern Med. 1996;  124 (5) 477-484
  • 127 Charlier C, Henegar C, Launay O et al.. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients.  Ann Rheum Dis. 2009;  68 (5) 658-663
  • 128 Faurschou M, Sorensen I J, Mellemkjaer L et al.. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.  J Rheumatol. 2008;  35 (1) 100-105
  • 129 Jayne D, Rasmussen N, Andrassy K European Vasculitis Study Group et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.  N Engl J Med. 2003;  349 (1) 36-44
  • 130 Reinhold-Keller E, Fink C O, Herlyn K, Gross W L, De Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate.  Arthritis Rheum. 2002;  47 (3) 326-332
  • 131 Pagnoux C, Mahr A, Hamidou M A French Vasculitis Study Group et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.  N Engl J Med. 2008;  359 (26) 2790-2803
  • 132 Hiemstra T F, Walsh M, Mahr A European Vasculitis Study Group (EUVAS) et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.  JAMA. 2010;  304 (21) 2381-2388
  • 133 Stone J H. Wegener's Granulomatosis Etanercept Trial Research Group . Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial.  Arthritis Rheum. 2003;  48 (8) 2299-2309
  • 134 Exley A R, Bacon P A, Luqmani R A, Kitas G D, Carruthers D M, Moots R. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI).  Br J Rheumatol. 1998;  37 (1) 57-63
  • 135 Stone J H, Hoffman G S, Merkel P A International Network for the Study of the Systemic Vasculitides (INSSYS) et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score.  Arthritis Rheum. 2001;  44 (4) 912-920
  • 136 Hoffman G S, Leavitt R Y, Fleisher T A, Minor J R, Fauci A S. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide.  Am J Med. 1990;  89 (4) 403-410
  • 137 de Groot K, Harper L, Jayne D R EUVAS (European Vasculitis Study Group) et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.  Ann Intern Med. 2009;  150 (10) 670-680
  • 138 Seror R, Pagnoux C, Ruivard M et al.. Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial.  Ann Rheum Dis. 2010;  69 2125-2130
  • 139 Jayne D. Leflunomide versus methotrexate in Wegener's granulomatosis.  Rheumatology (Oxford). 2007;  46 (7) 1047-1048
  • 140 Langford C A. Wegener's granulomatosis: current and upcoming therapies.  Arthritis Res Ther. 2003;  5 (4) 180-191
  • 141 Langford C A, Talar-Williams C, Sneller M C. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis.  Arthritis Rheum. 2000;  43 (8) 1836-1840
  • 142 De Groot K, Rasmussen N, Bacon P A et al.. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.  Arthritis Rheum. 2005;  52 (8) 2461-2469
  • 143 Langford C A, Talar-Williams C, Sneller M C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis.  Arthritis Rheum. 2004;  51 (2) 278-283
  • 144 Jones R B, Tervaert J W, Hauser T European Vasculitis Study Group et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.  N Engl J Med. 2010;  363 (3) 211-220
  • 145 Stone J H, Merkel P A, Spiera R RAVE-ITN Research Group et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.  N Engl J Med. 2010;  363 (3) 221-232
  • 146 Stegeman C A, Tervaert J W, de Jong P E, Kallenberg C G. Dutch Co-Trimoxazole Wegener Study Group . Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis.  N Engl J Med. 1996;  335 (1) 16-20
  • 147 Reinhold-Keller E, De Groot K, Rudert H, Nölle B, Heller M, Gross W L. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease.  QJM. 1996;  89 (1) 15-23
  • 148 Klemmer P J, Chalermskulrat W, Reif M S, Hogan S L, Henke D C, Falk R J. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis.  Am J Kidney Dis. 2003;  42 (6) 1149-1153
  • 149 Wang C C, Shiang J C, Tsai M K et al.. Prompt plasmapheresis successfully rescue pulmonary-renal syndrome caused by ANCA-negative microscopic polyangiitis.  Clin Rheumatol. 2009;  28 (12) 1457-1460
  • 150 Marder W, McCune W J. Advances in immunosuppressive therapy.  Semin Respir Crit Care Med. 2007;  28 (4) 398-417
  • 151 Haubitz M, Koch K M, Brunkhorst R. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis.  Nephrol Dial Transplant. 1998;  13 (8) 2074-2076
  • 152 Lynch III J P, McCune W J. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders.  Am J Respir Crit Care Med. 1997;  155 (2) 395-420
  • 153 Langford C A, Talar-Williams C, Barron K S, Sneller M C. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance.  Arthritis Rheum. 1999;  42 (12) 2666-2673
  • 154 Stone J H, Holbrook J T, Marriott M A Wegener's Granulomatosis Etanercept Trial Research Group et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.  Arthritis Rheum. 2006;  54 (5) 1608-1618
  • 155 Bernatsky S, Ramsey-Goldman R, Clarke A E. Malignancies and cyclophosphamide exposure in Wegener's granulomatosis.  J Rheumatol. 2008;  35 (1) 11-13
  • 156 Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up.  Rheumatology (Oxford). 2001;  40 (5) 492-498
  • 157 de Groot K, Adu D, Savage C O. EUVAS (European vasculitis study group) . The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.  Nephrol Dial Transplant. 2001;  16 (10) 2018-2027
  • 158 Sneller M C, Hoffman G S, Talar-Williams C, Kerr G S, Hallahan C W, Fauci A S. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone.  Arthritis Rheum. 1995;  38 (5) 608-613
  • 159 Langford C A, Sneller M C, Hoffman G S. Methotrexate use in systemic vasculitis.  Rheum Dis Clin North Am. 1997;  23 (4) 841-853
  • 160 de Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross W L. Induction of remission in Wegener's granulomatosis with low dose methotrexate.  J Rheumatol. 1998;  25 (3) 492-495
  • 161 Villa-Forte A, Clark T M, Gomes M et al.. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience.  Medicine (Baltimore). 2007;  86 (5) 269-277
  • 162 de Groot K, Reinhold-Keller E, Tatsis E et al.. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole.  Arthritis Rheum. 1996;  39 (12) 2052-2061
  • 163 Stone J H, Tun W, Hellman D B. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice.  J Rheumatol. 1999;  26 (5) 1134-1139
  • 164 Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude F J. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement.  J Am Soc Nephrol. 1999;  10 (9) 1965-1971
  • 165 Iatrou C, Zerbala S, Revela I et al.. Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement.  Clin Nephrol. 2009;  72 (1) 31-37
  • 166 Joy M S, Hogan S L, Jennette J C, Falk R J, Nachman P H. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis.  Nephrol Dial Transplant. 2005;  20 (12) 2725-2732
  • 167 Metzler C, Fink C, Lamprecht P, Gross W L, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis.  Rheumatology (Oxford). 2004;  43 (3) 315-320
  • 168 Metzler C, Miehle N, Manger K German Network of Rheumatic Diseases et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.  Rheumatology (Oxford). 2007;  46 (7) 1087-1091
  • 169 Henes J C, Kanz L, Koetter I. Rituximab and leflunomide for Wegener's granulomatosis: a long-term follow-up.  Rheumatol Int. 2011;  31 425-426
  • 170 Bremer J P, Ullrich S, Laudien M, Gross W L, Lamprecht P. Methotrexate plus leflunomide for the treatment of relapsing Wegener's granulomatosis: a retrospective uncontrolled study.  Clin Exp Rheumatol. 2010;  28 (1, suppl 57) 67-71
  • 171 Israel H L, Patchefsky A S, Saldana M J. Wegener's granulomatosis, lymphomatoid granulomatosis, and benign lymphocytic angiitis and granulomatosis of lung: recognition and treatment.  Ann Intern Med. 1977;  87 (6) 691-699
  • 172 Weiner S R, Paulus H E. Treatment of Wegener's granulomatosis.  Semin Respir Med. 1989;  10 156-161
  • 173 DeRemee R A. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision?.  Arthritis Rheum. 1988;  31 (8) 1068-1074
  • 174 Georgi J, Ulmer M, Gross W L. Cotrimoxazole in Wegener's granulomatosis—a prospective study [in German].  Immun Infekt. 1991;  19 (3) 97-98
  • 175 Hoffman G S. Immunosuppressive therapy is always required for the treatment of limited Wegener's granulomatosis.  Sarcoidosis Vasc Diffuse Lung Dis. 1996;  13 (3) 249-252
  • 176 Stegeman C A, Tervaert J W, Sluiter W J, Manson W L, de Jong P E, Kallenberg C G. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis.  Ann Intern Med. 1994;  120 (1) 12-17
  • 177 Falagas M E, Manta K G, Betsi G I, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review.  Clin Rheumatol. 2007;  26 (5) 663-670
  • 178 White E S, Lynch J P. Pharmacological therapy for Wegener's granulomatosis.  Drugs. 2006;  66 (9) 1209-1228
  • 179 Mukhtyar C, Luqmani R. Current state of tumour necrosis factor alpha blockade in Wegener's granulomatosis.  Ann Rheum Dis. 2005;  64 (suppl 4) iv31-iv36
  • 180 Specks U, Fervenza F C, McDonald T J, Hogan M C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.  Arthritis Rheum. 2001;  44 (12) 2836-2840
  • 181 Jayne D R, Chapel H, Adu D et al.. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.  QJM. 2000;  93 (7) 433-439
  • 182 Dick A D, Meyer P, James T et al.. Campath-1H therapy in refractory ocular inflammatory disease.  Br J Ophthalmol. 2000;  84 (1) 107-109
  • 183 Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).  Ann Rheum Dis. 2008;  67 (9) 1322-1327
  • 184 Lockwood C M. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy.  Clin Exp Immunol. 1996;  104 (suppl 1) 77-82
  • 185 Lockwood C M, Thiru S, Stewart S et al.. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies.  QJM. 1996;  89 (12) 903-912
  • 186 Jayne D R, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.  Mayo Clin Proc. 1997;  72 (8) 737-747
  • 187 Kool J, de Keizer R J, Siegert C E. Antithymocyte globulin treatment of orbital Wegener granulomatosis: a follow-up study.  Am J Ophthalmol. 1999;  127 (6) 738-739
  • 188 Schmitt W H, Birck R, Heinzel P A et al.. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients.  Nephrol Dial Transplant. 2005;  20 (6) 1083-1092
  • 189 Birck R, Warnatz K, Lorenz H M et al.. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy.  J Am Soc Nephrol. 2003;  14 (2) 440-447
  • 190 Flossmann O, Baslund B, Bruchfeld A et al.. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.  Ann Rheum Dis. 2009;  68 (7) 1125-1130
  • 191 Papo T, Le Thi Huong D, Wiederkehr J L et al.. Etoposide in Wegener's granulomatosis.  Rheumatology (Oxford). 1999;  38 (5) 473-475
  • 192 Stone J H, Uhlfelder M L, Hellmann D B, Crook S, Bedocs N M, Hoffman G S. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.  Arthritis Rheum. 2001;  44 (5) 1149-1154
  • 193 Clarke A E, Bitton A, Eappen R, Danoff D S, Esdaile J M. Treatment of Wegener's granulomatosis after renal transplantation: is cyclosporine the preferred treatment?.  Transplantation. 1990;  50 (6) 1047-1051
  • 194 Allen N B, Caldwell D S, Rice J R, McCallum R M. Cyclosporin A therapy for Wegener's granulomatosis.  Adv Exp Med Biol. 1993;  336 473-476
  • 195 Ghez D, Westeel P F, Henry I, Pruna A, Fournier A, Lassoued K. Control of a relapse and induction of long-term remission of Wegener's granulomatosis by cyclosporine.  Am J Kidney Dis. 2002;  40 (2) E6
  • 196 Koening C L, Hernández-Rodríguez J, Molloy E S, Clark T M, Hoffman G S. Limited utility of rapamycin in severe, refractory Wegener's granulomatosis.  J Rheumatol. 2009;  36 (1) 116-119
  • 197 Statkute L, Oyama Y, Barr W G et al.. Autologous non-myeloablative hematopoietic stem cell transplantation for refractory systemic vasculitis.  Ann Rheum Dis. 2008;  67 991-997
  • 198 Wegener's Granulomatosis Etanercept Trial (WGET) Research Group . Etanercept plus standard therapy for Wegener's granulomatosis.  N Engl J Med. 2005;  352 (4) 351-361
  • 199 Josselin L, Mahr A, Cohen P et al.. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients.  Ann Rheum Dis. 2008;  67 (9) 1343-1346
  • 200 Bartolucci P, Ramanoelina J, Cohen P et al.. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.  Rheumatology (Oxford). 2002;  41 (10) 1126-1132
  • 201 Booth A D, Jefferson H J, Ayliffe W, Andrews P A, Jayne D R. Safety and efficacy of TNFalpha blockade in relapsing vasculitis.  Ann Rheum Dis. 2002;  61 (6) 559
  • 202 Booth A, Harper L, Hammad T et al.. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.  J Am Soc Nephrol. 2004;  15 (3) 717-721
  • 203 Lamprecht P, Voswinkel J, Lilienthal T et al.. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis.  Rheumatology (Oxford). 2002;  41 (11) 1303-1307
  • 204 Hermann J, Reittner P, Scarpatetti M, Graninger W. Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab.  Ann Rheum Dis. 2006;  65 (5) 691-692
  • 205 Seror R, Mahr A, Ramanoelina J, Pagnoux C, Cohen P, Guillevin L. Central nervous system involvement in Wegener granulomatosis.  Medicine (Baltimore). 2006;  85 (1) 54-65
  • 206 Cheung C M, Murray P I, Savage C O. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab.  Br J Ophthalmol. 2005;  89 (11) 1542
  • 207 Ramos-Casals M, Brito-Zerón P, Muñoz S et al.. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.  Medicine (Baltimore). 2007;  86 (4) 242-251
  • 208 Hinze C H, Colbert R A. B-cell depletion in Wegener's granulomatosis.  Clin Rev Allergy Immunol. 2008;  34 372-379
  • 209 Stasi R, Stipa E, Del Poeta G, Amadori S, Newland A C, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.  Rheumatology (Oxford). 2006;  45 (11) 1432-1436
  • 210 Aries P M, Hellmich B, Voswinkel J et al.. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations.  Ann Rheum Dis. 2006;  65 (7) 853-858
  • 211 Keogh K A, Wylam M E, Stone J H, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.  Arthritis Rheum. 2005;  52 (1) 262-268
  • 212 Memet B, Rudinskaya A, Krebs T, Oelberg D. Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab.  J Clin Rheumatol. 2005;  11 (6) 314-318
  • 213 Tamura N, Matsudaira R, Hirashima M et al.. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab.  Intern Med. 2007;  46 (7) 409-414
  • 214 Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.  Scand J Rheumatol. 2005;  34 (3) 229-232
  • 215 Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.  Clin Exp Rheumatol. 2007;  25 (1, suppl 44) S23-S27
  • 216 Hermle T, Goestemeyer A K, Sweny P, Burns A. Successful therapeutic use of rituximab in refractory Wegener's granulomatosis after renal transplantation.  Clin Nephrol. 2007;  68 (5) 322-326
  • 217 Roccatello D, Baldovino S, Alpa M et al.. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement.  Clin Exp Rheumatol. 2008;  26 (3, suppl 49) S67-S71
  • 218 Jones R B, Ferraro A J, Chaudhry A N et al.. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.  Arthritis Rheum. 2009;  60 (7) 2156-2168
  • 219 Sharma A, Kumar S, Wanchu A et al.. Successful treatment of hypertrophic pachymeningitis in refractory Wegener's granulomatosis with rituximab.  Clin Rheumatol. 2010;  29 (1) 107-110
  • 220 Martinez Del Pero M, Chaudhry A, Jones R B, Sivasothy P, Jani P, Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.  Clin Otolaryngol. 2009;  34 (4) 328-335
  • 221 Taylor S R, Salama A D, Joshi L, Pusey C D, Lightman S L. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis.  Arthritis Rheum. 2009;  60 (5) 1540-1547
  • 222 Onal S, Kazokoglu H, Koc A, Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis.  Ocul Immunol Inflamm. 2008;  16 (5) 230-232
  • 223 Falk R J, Jennette J C. Rituximab in ANCA-associated disease.  N Engl J Med. 2010;  363 (3) 285-286
  • 224 Major E O. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.  Annu Rev Med. 2010;  61 35-47
  • 225 Ramos-Casals M, Soto M J, Cuadrado M J, Khamashta M A. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases.  Lupus. 2009;  18 (9) 767-776
  • 226 Kazatchkine M D, Kaveri S V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.  N Engl J Med. 2001;  345 (10) 747-755
  • 227 Ito-Ihara T, Ono T, Nogaki F et al.. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis.  Nephron Clin Pract. 2006;  102 (1) c35-c42
  • 228 Martinez V, Cohen P, Pagnoux C French Vasculitis Study Group et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients.  Arthritis Rheum. 2008;  58 (1) 308-317
  • 229 Schmitt W H, Hagen E C, Neumann I, Nowack R, Flores-Suárez L F, van der Woude F J. European Vasculitis Study Group . Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients.  Kidney Int. 2004;  65 (4) 1440-1448
  • 230 Flossmann O, Jayne D R. Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin.  Rheumatology (Oxford). 2010;  49 (3) 556-562
  • 231 Imai H, Hotta O, Yoshimura M et al.. Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy.  Clin Exp Nephrol. 2006;  10 (1) 40-54
  • 232 Birck R, Newman M, Braun C et al.. 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis.  Nephrol Dial Transplant. 2006;  21 (1) 58-63
  • 233 Krafcik S S, Covin R B, Lynch III J P, Sitrin R G. Wegener's granulomatosis in the elderly.  Chest. 1996;  109 (2) 430-437
  • 234 Koldingsnes W, Nossent J C. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis.  J Rheumatol. 2003;  30 (1) 80-88
  • 235 Orens J B, Sitrin R G, Lynch III J P. The approach to nonresolving pneumonia.  Med Clin North Am. 1994;  78 (5) 1143-1172
  • 236 Lynch III J P, Raghu G. Major disease syndromes of unknown etiology. In: Baum G, Crapo J, eds. Textbook of Pulmonary Disease. 6th ed. Boston, MA: Little, Brown; 1998: 431-476
  • 237 Lynch III J P, Matteson E, McCune J W. Wegener's granulomatosis: evolving concepts.  Medical Rounds. 1989;  2 67-80

Joseph P LynchIII M.D. 

Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, The David Geffen School of Medicine at UCLA

10833 Le Conte Ave., Rm. 37-131 CHS, Los Angeles, CA 90095-1690

Email: jplynch@mednet.ucla.edu

    >